Crohn’s & Colitis 360

Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn’s Disease

United European Gastroenterology (UEG) Week 2020

Early and Durable Symptom Control in Patients with Moderately to Severely Active Ulcerative Colitis Treated with Etrasimod (APD334) in the Randomised, Double Blind, Placebo Controlled, Phase 2 OASIS Trial and Open Label Extension

United European Gastroenterology (UEG) Week 2020

The Incremental Increasing Rate of Thromboembolic Events in Patients with Inflammatory Bowel Disease Compared to Patients without Autoimmune Disorder

American College of Gastroenterology Annual Scientific Meeting (ACG) 2020

Early and Durable Symptom Control in Patients with Moderately to Severely Active Ulcerative Colitis Treated with Etrasimod (APD334) in the Randomized, Double Blind, Placebo Controlled Phase 2 OASIS Trial and Open Label Extension

American College of Gastroenterology Annual Scientific Meeting (ACG) 2020

The Incremental Rate of Thromboembolic Events in Patients with Inflammatory Bowel Disease Compared to Patients without Immune-Mediated Diseases

Examining the Link between Autoimmune Disease and Thromboembolic Events: A Modified Delphi Panel Approach

Patient-reported Disease Activity in a Large Sample of Ulcerative Colitis (UC) Patients Using Social-Media Delivered Questionnaires

Risk Factors for Thromboembolic Events among Patients with Immune-Mediated Diseases

Journal of Crohn’s & Colitis

Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study

Digestive Disease Week (DDW) 2020

Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2 (CB2), Reduces Visceral Hypersensitivity in Mice

1 2 3 4

For Medical Information, contact us at medinfo@arenapharm.com